` VCC2 (Brickell Biotech Inc) vs DAX Index Comparison - Alpha Spread

VCC2
vs
DAX Index

Over the past 12 months, VCC2 has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's 30% growth.

Stocks Performance
VCC2 vs DAX Index

Loading
VCC2
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
VCC2 vs DAX Index

Loading
VCC2
DAX Index
Difference
www.alphaspread.com

Performance By Year
VCC2 vs DAX Index

Loading
VCC2
DAX Index
Add Stock

Competitors Performance
Brickell Biotech Inc vs Peers

DAX Index
VCC2
ABBV
AMGN
GILD
VRTX
Add Stock

Brickell Biotech Inc
Glance View

Market Cap
16m EUR
Industry
Biotechnology

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 16 full-time employees. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.

VCC2 Intrinsic Value
Not Available
B
Back to Top